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Population studies indicate a continuous association be-
tween an increase in attributable risk for cardiovascular
disease with increasing blood pressure (BP) and age (1).
Resistant hypertension, by deﬁnition, is the inability to
reduce BP to levels <140/90 mm Hg, despite adequate
combinations of maximally tolerated doses of antihyper-
tensive medications and lifestyle modiﬁcations (2). The
longer history of higher sustained pressures, relative to those
without resistant hypertension, increases the likelihood of
end-organ injury such as left ventricular (LV) hypertrophy,
subsequent heart failure, and progression of kidney disease.See page 1916The pathophysiology of resistant hypertension is not well
understood, but the sympathetic nervous system (SNS) has
a central role in its genesis (3). Antihypertensive medica-
tions that inhibit the beta- or alpha-adrenoreceptors are
only partially effective in inhibiting the SNS effects of
primary hypertension and relatively ineffective in true
resistant hypertension. New interventional techniques in
man help attenuate the effects of the SNS on BP, with 1
such technique being renal denervation. Renal denervation
has now garnered a reasonable database demonstrating
improvement, not only in BP control among patients with
true resistance, but also in other comorbid conditions such
as glycemic control, LV hypertrophy, and sleep apnea (4).
Speciﬁcally, recent reports have linked renal denervation
with reduction in LV mass and improved cardiac perfor-
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ductions in LV mass and improved diastolic relaxation
realized within 6 months following renal denervation in 66
patients prospectively studied who underwent planned renal
denervation at a single European center (using the Med-
tronic Flex catheter system; Medtronic, Santa Rosa, Cali-
fornia) (6). These improvements in cardiac function and
ventricular size were documented by changes in echocardi-
ography and independent of the magnitude of BP reduction.
Unlike previous studies on LV mass regression, the novelty
of this study was that neither BP at baseline nor degree to
which BP was reduced had an impact on the degree of LV
mass regression or diastolic improvement (6). The authors
therefore concluded that renal denervation results in
amelioration of not only BP load, but other unexplained
variables that contribute to ventricular hypertrophy.
The ﬁndings of this study, although intriguing, raise a
number of issues. First, the present study drew its conclu-
sions from a relatively small sample size of patients, all
undergoing open-label catheter renal denervation at a single
center, without a sham control for comparison. This prob-
lem is offset, partially, by a subset of patients with 24-h
ambulatory monitoring data.
The authors presented medications used at baseline but
did not present data on kidney function. It is well known
that chronic kidney disease (i.e., estimated glomerular
ﬁltration rate <60 ml/min/1.73 m2) is strongly associated
with increases in LV mass and is a contributing factor to
resistant hypertension (7). Online Table 1 in the article by
Schirmer et al. (6) lists the patients as requiring a mean of
4.3 antihypertensive medications at baseline, with higher
usage of beta-blockers (89%) and diuretics (100%), and
proportionally lower use of angiotensin receptor blockers
(55%). An early meta-analysis demonstrated that beta-
blockers have little to no effect on regression of LV mass
(8). A more recent meta-analysis of 4,000 patients further
supports these earlier ﬁndings by showing differences be-
tween drug classes on LV mass reduction, after adjustment
for the degree and duration of BP reduction. This meta-
analysis noted an 11% regression with calcium channel
blockers, 10% with angiotensin-converting enzyme in-
hibitors, 8% with diuretics, and 6% with beta-blockers (9).
This lack of effect on LV mass regression by beta-blockers,
however, is only seen when BP levels are approximately
140/90 mm Hg. A recent randomized multicenter trial of
patients with BP <130/80 mm Hg showed comparable LV
mass regression using magnetic resonance imaging in pa-
tients randomized to carvedilol CR/lisinopril versus ateno-
lol/lisinopril versus high-dose lisinopril (10). Thus, although
the investigators of the present study indicated that there
were no signiﬁcant adjustments to medication regimens
between the start and conclusion of the study, detailed
information stratiﬁed by tertile of treatment response was
not provided. Consequently, given the small sample size, the
beneﬁt seen in the lowest BP tertile may be attributable
to better BP control.
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diography, rather than magnetic resonance imaging, widely
regarded as the reference standard for LV mass quantiﬁca-
tion, especially at 6 months. One may presume, however,
that differences between these assessment methodologies
should not have had a signiﬁcant impact on the ﬁndings
because echocardiography for all assessments was performed
by a single blinded operator, and so limitations of assessment
should have uniformly carried through the study.
Another consideration relates to renovascular anatomy
and the actual performance of the renal denervation proce-
dure, details of which are limited in the report. The quality
of denervation may have also contributed to a more effective
ablation of sympathetic trafﬁc and hence, a greater LV mass
regression. Recommendations relating to anatomic suit-
ability put forth by the expert consensus document from the
European Society of Cardiology include selection of renal
arteries with an ablatable segment >20 mm in length and
a diameter of >4 mm (11). We assume from the paucity of
detail that all 66 patients conformed to these recommen-
dations, but information on the presence of accessory renal
arteries, early branching of main renal arteries, and sizing of
branches not intervened upon would all be relevant. Addi-
tionally, the speciﬁcs of radiofrequency ablation were not
provided vis-à-vis the number of ablation sites per vessel and
per patient, catheter tip temperature, and total energy
delivered. These variables could potentially serve as surro-
gates for the adequacy of interruption in renal sympathetic
signaling and thus, bear great relevance to the observed
results. Even if this information were in hand, an admitted
limitation to the denervation system employed in this study
is interoperator variability introduced by the requisite
manipulation of a single-tip, unipolar device in a spiral
fashion within each renal artery and ﬂuctuation of electrical
impedance during delivery of radiofrequency energy. Thus,
these results may not be generalizable to all centers doing
the procedure.
Finally, the SNS does interact with the renin-angiotensin
system, and activation of one system is usually associated
with activation of the other, with the converse also being
true (12,13). Hence, it is possible that renal denervation
reduced the renin-angiotensin system, thus acting like a
renin-angiotensin system blocker and providing this addi-
tional beneﬁt on LV mass regression.
In summary, Schirmer et al. (6) should be commended
for providing promising early beneﬁt of catheter-based
renal denervation and for highlighting a possibleBP-independent facet of this technique. These observations
need conﬁrmation before acceptance in clinical practice
for the reasons enumerated previously and can only be
applied to those with inclusion criteria used in their study.
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